Cristina Zannori

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman et al. · Journal for ImmunoTherapy of Cancer · 2023 · 73 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip et al. · Journal of Thoracic Oncology · 2019 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Could thymomectomy be a reasonable option for non-myasthenic thymoma patients?

Valentina Tassi, Silvia Ceccarelli, Cristina Zannori et al. · Journal of Thoracic Disease · 2017 · 19 citations · Full text

Medicine, Oncology, Surgery +11

STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial

Fabio Arcidiacono, Paola Anselmo, Michelina Casale et al. · International Journal of Radiation Oncology*Biology*Physics · 2022 · 18 citations

Medicine, Oncology, Radiation Oncology +13

Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip et al. · Annals of Oncology · 2019 · 17 citations

Medicine, Oncology, Pharmacotherapy +6